CHS on facebook and YouTube
Second editions of three booklets now available
Products in the pipeline - NEW UPDATE (December 16, 2014)
Click here for more details.
HIRT? - An innovative injury self-management App
Do you have mild hemophilia?
Have you had injuries that seemed minor at first but then turned into a more serious problem?
Not sure what to do when you have a bleed?
Then HIRT? (Hemophilia Injury Recognition Tool) is just what you need!
This new App, developed following research funded by the CHS/Baxter Canada Inherited Bleeding Disorders Fellowship Program for Nurses and Allied Health Care Professionals, was designed with the help and feedback from young men age 18-35 with mild hemophilia.
Click here for all the details.
Great stories from the Pfizer “Take a Happy Break” contest
Click here to read more about Laura and her son Brandon’s story.
Click here to read more about Jenny and her son Caleb’s story.
CHS support to research and market studies
These studies, however, need our community to gather sufficient data to be relevant.
Please take the time to see what is presently happening with regards to research and market studies and to see if you could take an active part in them.
On-going RESEARCH studies currently recruiting participants:
- Invitation to families of children with bleeding disorders to participate in an interview-based research study
- Do you have mild hemophilia?
- Carriers of hemophilia wanted for survey-based research study
- Web survey about perceived well-being in people with hemophilia
Click here for more details on each of these research studies.
On-going MARKET studies currently recruiting participants:
- Absolutdata is currently looking for adults and youth as well as parents of children with hemophilia A for a market research study.
- HealthPulse is currently looking for patients with hemophilia A and a low titre inhibitor who are undergoing immune tolerance induction (ITI) therapy or who are currently being treated with a bypassing agent (Niastase, FEIBA).
Click here for more details on each of these market studies.
E-novella spreading the word on bleeding disorders on Wattpad
Playing off the popular Harlequin romance genre, ‘A Negative’ tells the story of a young woman unknowingly living with von Willebrand disease. We’ve published the e-novella on Wattpad – the world’s largest online community of writers and readers – in order to connect with young women across Canada. This unique approach introduces the issue into a different medium, enabling us to speak to and educate an engaged but unsuspecting audience.
CLICK HERE for the press release.
CLICK HERE to read 'A Negative'.
Hemophilia Today - November 2014
Second study suggests higher risk of inhibitors with Kogenate/Helixate in previously untreated patients with hemophilia A
In January 2013, the Research of Determinants of Inhibitor Development (RODIN) study group also reported a similarly higher risk of inhibitor development in PUPs treated with this second-generation full-length rFVIII, Kogenate FS/Helixate FS, compared to all other FVIII products.
At that time, the Association of Hemophilia Clinic Directors of Canada recommended to its members that they “consider these findings as a factor in their decision-making regarding product choice for newly diagnosed PUPs with severe hemophilia A.”
The RODIN study was reviewed by regulators and, in December 2013, the European Medicines Agency’s (EMA) concluded that the benefits of Kogenate FS/Helixate NexGen (Helixate FS in Canada) continue to outweigh their risks in PUPs with hemophilia A.
Following the most recent paper, however, the World Federation of Hemophilia’s Therapeutic Products Safety, Supply and Availability Committee (TPSSAC) issued a statement which said: “Based on the available published data, it may be prudent, where other safe clotting factor concentrates are available, to consider not using Kogenate FS/Helixate NexGen for newly diagnosed PUPs with severe hemophilia A.” The WFH TPSSAC also stated: “There is no evidence of a higher risk of inhibitors with this product in previously treated patients.” Click here for the complete statement.
Regulatory agencies such as the EMA and the U.S. FDA are evaluating this latest data on inhibitor development. Both the CHS Blood Safety and Supply Committee and the WFH TPSSAC are monitoring developments. Please check on the CHS and WFH Web sites for updates.
Health Canada has issued a Notice of Compliance (NOC) for Harvoni (ledipasvir/sofosbuvir)
Click here for the details of the announcement.
NEW CHS resources about HCV treatment support for 1986-1990 claimants
If you are a patient who received tainted blood or blood products and a registered claimant of the Hepatitis C (HCV) 1986-1990 Class Actions Settlement, now is a good time to speak to your doctor about new treatments for HCV. Treatment has progressed significantly, and it may be the right time for you to seek a cure.
People who are approved claimants under the Hepatitis C January 1, 1986 — July 1, 1990 Class Actions Settlement may be reimbursed for their costs for treatments and generally accepted hepatitis C medications that are not recoverable under any public or private health care plan. Moreover, thanks to a collaborative effort between the CHS and Gilead Health Sciences Canada, The Momentum Support Program can now provide upfront payments to those eligible for the high-cost treatment Sovaldi (sofosbuvir) while the claimants wait for a reimbursement from the 1986-1990 plan.
Because this is not well known by the claimants themselves nor their health care providers, the CHS has developed a new resource to provide more information.
Please click here for more information and access to the new brochure.
A bandage is not enough.
HELP SPREAD THE WORD ABOUT INHERITED BLEEDING DISORDERS.
Click here for more information about this important public awareness and outreach campaign or to download promotional material.
You and your family depend on research...
Make a difference - Help save lives
We can stop the suffering of those living with hemophilia and other bleeding disorders. But we can't do it alone. Only with the generous financial support of caring Canadians can we make our dream come true.
To support us